Randomized discontinuation trial of sorafenib (BAY 43-9006)

Lokesh Jain; Jürgen Venitz; William D. Figg

doi:10.4161/cbt.5.10.3290

Randomized discontinuation trial of sorafenib (BAY 43-9006)

Lokesh Jain, Jürgen Venitz, William D. Figg^*

^*Corresponding author for this work

Research output: Contribution to journal › Short survey › peer-review

5 Scopus citations

Abstract

With the increasing interest in development of cytostatic anticancer drugs, the randomized discontinuation trial (RDT) design has been proved to be useful in the evaluation of their clinical activity. In the June 1, 2006 issue of the Journal of Clinical Oncology, a study by Ratain et al. uses RDT in a phase-II placebo controlled study to evaluate the efficacy of sorafenib (BAY 43-9006) in patients with metastatic renal cell carcinoma (RCC). The results from their investigation affirm the merits of the RDT in testing the efficacy of cytostatic drugs and also prove the significant disease-stabilizing activity and tolerability of sorafenib in metastatic renal cell carcinoma.

Original language	English
Pages (from-to)	1270-1272
Number of pages	3
Journal	Cancer Biology and Therapy
Volume	5
Issue number	10
DOIs	https://doi.org/10.4161/cbt.5.10.3290
State	Published - Oct 2006
Externally published	Yes

Keywords

Cytostatic
Kinase inhibitor
Phase-II
Renal cell carcinoma

Access to Document

10.4161/cbt.5.10.3290

Cite this

@article{0dd4a3163884467c8616d4013554941d,

title = "Randomized discontinuation trial of sorafenib (BAY 43-9006)",

abstract = "With the increasing interest in development of cytostatic anticancer drugs, the randomized discontinuation trial (RDT) design has been proved to be useful in the evaluation of their clinical activity. In the June 1, 2006 issue of the Journal of Clinical Oncology, a study by Ratain et al. uses RDT in a phase-II placebo controlled study to evaluate the efficacy of sorafenib (BAY 43-9006) in patients with metastatic renal cell carcinoma (RCC). The results from their investigation affirm the merits of the RDT in testing the efficacy of cytostatic drugs and also prove the significant disease-stabilizing activity and tolerability of sorafenib in metastatic renal cell carcinoma.",

keywords = "Cytostatic, Kinase inhibitor, Phase-II, Renal cell carcinoma",

author = "Lokesh Jain and J{\"u}rgen Venitz and Figg, {William D.}",

year = "2006",

month = oct,

doi = "10.4161/cbt.5.10.3290",

language = "English",

volume = "5",

pages = "1270--1272",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

number = "10",

}

TY - JOUR

T1 - Randomized discontinuation trial of sorafenib (BAY 43-9006)

AU - Jain, Lokesh

AU - Venitz, Jürgen

AU - Figg, William D.

PY - 2006/10

Y1 - 2006/10

N2 - With the increasing interest in development of cytostatic anticancer drugs, the randomized discontinuation trial (RDT) design has been proved to be useful in the evaluation of their clinical activity. In the June 1, 2006 issue of the Journal of Clinical Oncology, a study by Ratain et al. uses RDT in a phase-II placebo controlled study to evaluate the efficacy of sorafenib (BAY 43-9006) in patients with metastatic renal cell carcinoma (RCC). The results from their investigation affirm the merits of the RDT in testing the efficacy of cytostatic drugs and also prove the significant disease-stabilizing activity and tolerability of sorafenib in metastatic renal cell carcinoma.

AB - With the increasing interest in development of cytostatic anticancer drugs, the randomized discontinuation trial (RDT) design has been proved to be useful in the evaluation of their clinical activity. In the June 1, 2006 issue of the Journal of Clinical Oncology, a study by Ratain et al. uses RDT in a phase-II placebo controlled study to evaluate the efficacy of sorafenib (BAY 43-9006) in patients with metastatic renal cell carcinoma (RCC). The results from their investigation affirm the merits of the RDT in testing the efficacy of cytostatic drugs and also prove the significant disease-stabilizing activity and tolerability of sorafenib in metastatic renal cell carcinoma.

KW - Cytostatic

KW - Kinase inhibitor

KW - Phase-II

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33751116295&partnerID=8YFLogxK

U2 - 10.4161/cbt.5.10.3290

DO - 10.4161/cbt.5.10.3290

M3 - Short survey

C2 - 16969070

AN - SCOPUS:33751116295

SN - 1538-4047

VL - 5

SP - 1270

EP - 1272

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 10

ER -

Randomized discontinuation trial of sorafenib (BAY 43-9006)

Abstract

Keywords

Access to Document

Fingerprint

Cite this